NO320908B1 - Granulformulering, fremgangsmate til fremstilling derav, anvendelse derav for behandling av sykdommer, samt pose som inneholder formuleringen. - Google Patents
Granulformulering, fremgangsmate til fremstilling derav, anvendelse derav for behandling av sykdommer, samt pose som inneholder formuleringen. Download PDFInfo
- Publication number
- NO320908B1 NO320908B1 NO20021394A NO20021394A NO320908B1 NO 320908 B1 NO320908 B1 NO 320908B1 NO 20021394 A NO20021394 A NO 20021394A NO 20021394 A NO20021394 A NO 20021394A NO 320908 B1 NO320908 B1 NO 320908B1
- Authority
- NO
- Norway
- Prior art keywords
- formulation
- binder
- granules
- formulation according
- granule
- Prior art date
Links
- 239000008187 granular material Substances 0.000 title claims description 62
- 238000009472 formulation Methods 0.000 title claims description 52
- 239000000203 mixture Substances 0.000 title claims description 52
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 6
- 201000010099 disease Diseases 0.000 title claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 5
- 239000011230 binding agent Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims 1
- 238000005243 fluidization Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 20
- 239000012736 aqueous medium Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000375 suspending agent Substances 0.000 description 7
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 5
- 229960005197 quetiapine fumarate Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 4
- 229940035004 seroquel Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 3
- 229960004431 quetiapine Drugs 0.000 description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922271.3A GB9922271D0 (en) | 1999-09-21 | 1999-09-21 | Formulation |
| PCT/GB2000/003598 WO2001021179A1 (en) | 1999-09-21 | 2000-09-18 | Quetiapine granules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20021394D0 NO20021394D0 (no) | 2002-03-20 |
| NO20021394L NO20021394L (no) | 2002-03-20 |
| NO320908B1 true NO320908B1 (no) | 2006-02-13 |
Family
ID=10861288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021394A NO320908B1 (no) | 1999-09-21 | 2002-03-20 | Granulformulering, fremgangsmate til fremstilling derav, anvendelse derav for behandling av sykdommer, samt pose som inneholder formuleringen. |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US6599897B1 (zh) |
| EP (1) | EP1218009B1 (zh) |
| JP (1) | JP2003509461A (zh) |
| KR (1) | KR100748823B1 (zh) |
| CN (3) | CN1331472C (zh) |
| AR (1) | AR032596A1 (zh) |
| AT (1) | ATE288272T1 (zh) |
| AU (1) | AU776292B2 (zh) |
| BG (1) | BG65469B1 (zh) |
| BR (1) | BR0014107A (zh) |
| CA (1) | CA2383131A1 (zh) |
| CO (1) | CO5180585A1 (zh) |
| CZ (1) | CZ301585B6 (zh) |
| DE (1) | DE60017923T2 (zh) |
| DK (1) | DK1218009T3 (zh) |
| EE (1) | EE200200150A (zh) |
| EG (1) | EG24226A (zh) |
| ES (1) | ES2235941T3 (zh) |
| GB (2) | GB9922271D0 (zh) |
| HK (1) | HK1047706B (zh) |
| HU (1) | HUP0203531A3 (zh) |
| IL (2) | IL148440A0 (zh) |
| IS (1) | IS2139B (zh) |
| MX (1) | MXPA02002627A (zh) |
| MY (1) | MY130208A (zh) |
| NO (1) | NO320908B1 (zh) |
| NZ (1) | NZ517549A (zh) |
| PL (1) | PL198824B1 (zh) |
| PT (1) | PT1218009E (zh) |
| RU (1) | RU2256453C2 (zh) |
| SI (1) | SI1218009T1 (zh) |
| SK (1) | SK286884B6 (zh) |
| TR (1) | TR200200716T2 (zh) |
| TW (1) | TWI226832B (zh) |
| UA (1) | UA73529C2 (zh) |
| WO (1) | WO2001021179A1 (zh) |
| ZA (1) | ZA200201709B (zh) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| SE0102855D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
| WO2003039516A1 (en) * | 2001-11-07 | 2003-05-15 | Fujisawa Pharmaceuticla Co., Ltd. | Method for improving dissolution of poorly dispersible medicaments |
| JP4514473B2 (ja) * | 2004-02-23 | 2010-07-28 | 富士通株式会社 | コンピュータシステム、中央装置及びプログラム実行方法 |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| WO2006117700A2 (en) * | 2005-04-21 | 2006-11-09 | Medichem, S.A. | Process for preparing quetiapine and quetiapine fumarate |
| EP1976487A2 (en) | 2006-01-25 | 2008-10-08 | Astron Research Limited | Sustained release dosage form of phenothiazine derivatives containing channelizer |
| TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| EP2133338A1 (en) * | 2006-05-09 | 2009-12-16 | AstraZeneca AB | Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine |
| CA2657202A1 (en) * | 2006-07-28 | 2008-01-31 | Farmaprojects, S.A. | Extended release pharmaceutical formulation of metoprolol and process for its preparation |
| AR062860A1 (es) * | 2006-09-15 | 2008-12-10 | Astrazeneca Ab | Combinaciones terapeuticas 482 |
| WO2008052354A1 (en) * | 2006-11-03 | 2008-05-08 | University Of Saskatchewan | Method of treating demyelination diseases |
| US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
| ATE480227T1 (de) * | 2007-02-14 | 2010-09-15 | Lesvi Laboratorios Sl | Pharmazeutische zusammensetzungen mit quetiapinfumarat |
| JP2011512818A (ja) * | 2008-02-27 | 2011-04-28 | キャドバリー アダムス ユーエスエー エルエルシー | 複数領域菓子 |
| EA018638B1 (ru) | 2008-08-01 | 2013-09-30 | Крка, Товарна Здравил, Д. Д., Ново Место | Композиция кветиапина |
| DE102008046650A1 (de) | 2008-09-10 | 2010-03-11 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Quetiapin enthaltende Retardtablette |
| US8715699B2 (en) | 2009-12-31 | 2014-05-06 | Kempharm, Inc. | Amino acid conjugates of quetiapine, process for making and using the same |
| EP2544536B1 (en) | 2010-03-11 | 2018-12-12 | Kempharm, Inc. | Fatty acid conjugates of quetiapine, process for making and using the same |
| KR20130081221A (ko) | 2010-05-20 | 2013-07-16 | 아스트라제네카 아베 | 아릴 치환된 올레핀계 아민의 신규 제조 방법 |
| DE102010033527A1 (de) | 2010-08-05 | 2012-02-09 | Acino Pharma Ag | Quetiapin-Tabletten |
| DE102011115690A1 (de) | 2011-10-11 | 2013-04-11 | Acino Pharma Ag | Quetiapin enthaltende Formulierungen |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| GB8705574D0 (en) * | 1987-03-10 | 1987-04-15 | Ici Plc | Preparation of thiazepine compound |
| ATE86111T1 (de) * | 1989-08-31 | 1993-03-15 | Takeda Chemical Industries Ltd | Vitamin-b12-zusammensetzung. |
| IT1250701B (it) * | 1991-07-24 | 1995-04-21 | Angelini Francesco Ist Ricerca | Composizione farmaceutica solida per uso orale a base di dapiprazolo |
| JPH06100602A (ja) * | 1992-09-18 | 1994-04-12 | Asahi Chem Ind Co Ltd | 経口固形製剤およびその製造方法 |
| US5397576A (en) * | 1992-09-23 | 1995-03-14 | Hoffmann-La Roche Inc. | Spray triturated micronutrient compositions |
| ZA973433B (en) * | 1996-04-24 | 1997-12-10 | Shionogi & Co | A sertindole-containing preparation and a method for producing the same. |
| US5948437A (en) | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
| BR9713215A (pt) * | 1996-09-24 | 2000-04-04 | Lilly Co Eli | Formulação de partìcula revestida |
| US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
-
1999
- 1999-09-21 GB GBGB9922271.3A patent/GB9922271D0/en not_active Ceased
-
2000
- 2000-09-01 GB GBGB0021406.4A patent/GB0021406D0/en not_active Ceased
- 2000-09-18 DK DK00960855T patent/DK1218009T3/da active
- 2000-09-18 EP EP00960855A patent/EP1218009B1/en not_active Expired - Lifetime
- 2000-09-18 NZ NZ517549A patent/NZ517549A/en not_active IP Right Cessation
- 2000-09-18 AT AT00960855T patent/ATE288272T1/de active
- 2000-09-18 MX MXPA02002627A patent/MXPA02002627A/es active IP Right Grant
- 2000-09-18 CN CNB2004101011599A patent/CN1331472C/zh not_active Expired - Lifetime
- 2000-09-18 HU HU0203531A patent/HUP0203531A3/hu unknown
- 2000-09-18 CA CA002383131A patent/CA2383131A1/en not_active Abandoned
- 2000-09-18 JP JP2001524605A patent/JP2003509461A/ja active Pending
- 2000-09-18 RU RU2002110456/15A patent/RU2256453C2/ru not_active IP Right Cessation
- 2000-09-18 CZ CZ20020974A patent/CZ301585B6/cs not_active IP Right Cessation
- 2000-09-18 WO PCT/GB2000/003598 patent/WO2001021179A1/en active IP Right Grant
- 2000-09-18 BR BR0014107-0A patent/BR0014107A/pt not_active Application Discontinuation
- 2000-09-18 CN CNB00813166XA patent/CN1188130C/zh not_active Expired - Lifetime
- 2000-09-18 CN CNA2006101007643A patent/CN1899288A/zh active Pending
- 2000-09-18 PT PT00960855T patent/PT1218009E/pt unknown
- 2000-09-18 TR TR2002/00716T patent/TR200200716T2/xx unknown
- 2000-09-18 IL IL14844000A patent/IL148440A0/xx active IP Right Grant
- 2000-09-18 KR KR1020027003676A patent/KR100748823B1/ko not_active IP Right Cessation
- 2000-09-18 EE EEP200200150A patent/EE200200150A/xx unknown
- 2000-09-18 UA UA2002043283A patent/UA73529C2/uk unknown
- 2000-09-18 US US10/088,804 patent/US6599897B1/en not_active Expired - Lifetime
- 2000-09-18 DE DE60017923T patent/DE60017923T2/de not_active Expired - Lifetime
- 2000-09-18 SI SI200030640T patent/SI1218009T1/xx unknown
- 2000-09-18 AU AU73023/00A patent/AU776292B2/en not_active Ceased
- 2000-09-18 SK SK372-2002A patent/SK286884B6/sk not_active IP Right Cessation
- 2000-09-18 ES ES00960855T patent/ES2235941T3/es not_active Expired - Lifetime
- 2000-09-18 PL PL357369A patent/PL198824B1/pl unknown
- 2000-09-19 CO CO00070974A patent/CO5180585A1/es not_active Application Discontinuation
- 2000-09-19 MY MYPI20004370A patent/MY130208A/en unknown
- 2000-09-20 TW TW089119338A patent/TWI226832B/zh not_active IP Right Cessation
- 2000-09-20 EG EG20001205A patent/EG24226A/xx active
- 2000-09-21 AR ARP000104954A patent/AR032596A1/es unknown
-
2002
- 2002-02-27 IL IL148440A patent/IL148440A/en not_active IP Right Cessation
- 2002-02-28 ZA ZA200201709A patent/ZA200201709B/en unknown
- 2002-03-11 BG BG106509A patent/BG65469B1/bg unknown
- 2002-03-19 IS IS6308A patent/IS2139B/xx unknown
- 2002-03-20 NO NO20021394A patent/NO320908B1/no not_active IP Right Cessation
- 2002-12-27 HK HK02109363.8A patent/HK1047706B/zh not_active IP Right Cessation
-
2003
- 2003-07-25 US US10/627,198 patent/US7022692B2/en not_active Expired - Fee Related
-
2006
- 2006-01-10 US US11/329,378 patent/US20060159768A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO320908B1 (no) | Granulformulering, fremgangsmate til fremstilling derav, anvendelse derav for behandling av sykdommer, samt pose som inneholder formuleringen. | |
| WO2015071668A1 (en) | Pharmaceutical compositions | |
| US20050003001A1 (en) | Method for improving dissolution of poorly dispersible medicaments | |
| CN104650091A (zh) | 替格瑞洛的微粉化及其晶型,以及制备方法和药物应用 | |
| CN112312912B (zh) | 含有二胺衍生物的颗粒 | |
| NZ224497A (en) | Pharmaceutical composition comprising flunarizine | |
| WO2013066616A1 (en) | Pazopanib formulation | |
| WO2022234408A1 (en) | Alpelisib formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |